Variant position: 709 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1210 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human VEPLTPSGEAPNQALLRILK ETEFKKIKVLGSGAFGTVYKG
Rhesus macaque VEPLTPSGEAPNQALLRILK ETEFKKIKVLGSGAFGTVYKG
Mouse VEPLTPSGEAPNQAHLRILK ETEFKKIKVLGSGAFGTVYKG
Drosophila SEPLRPSNIGANLCKLRIVK DAELRKGGVLGMGAFGRVYKG
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
25 – 1210 Epidermal growth factor receptor
669 – 1210 Cytoplasmic
693 – 693 Phosphothreonine; by PKD/PRKD1
695 – 695 Phosphoserine
716 – 716 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
406 – 1210 Missing. In isoform 2.
629 – 1210 Missing. In isoform 4.
706 – 1210 Missing. In isoform 3.
689 – 689 V -> A. Reduced autophosphorylation.
689 – 689 V -> M. Constitutively activated kinase.
690 – 690 E -> A. Reduced phosphorylation.
692 – 692 L -> AP. Strongly reduced phosphorylation.
693 – 693 T -> A. Increased phosphorylation.
693 – 693 T -> D. Strongly reduced phosphorylation.
694 – 694 P -> A. Strongly reduced phosphorylation.
699 – 699 P -> A. Reduced phosphorylation.
700 – 700 N -> A. Abolishes phosphorylation.
704 – 704 L -> A. Abolishes phosphorylation.
705 – 705 R -> A. Abolishes phosphorylation.
706 – 706 I -> A. Abolishes phosphorylation.
709 – 711
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang S.F.; Liu H.P.; Li L.H.; Ku Y.C.; Fu Y.N.; Tsai H.Y.; Chen Y.T.; Lin Y.F.; Chang W.C.; Kuo H.P.; Wu Y.C.; Chen Y.R.; Tsai S.F.;
Clin. Cancer Res. 10:8195-8203(2004)
Cited for: VARIANTS ALA-709; GLY-709; CYS-719; SER-719; 746-GLU--ALA-750 DEL; 746-GLU--THR-751 DELINS ALA; 746-GLU--SER-752 DELINS ASP; 747-LEU--THR-751 DEL; ILE-768; MET-769; VAL-833; LEU-835; VAL-838; ARG-858 AND GLN-861;
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam I.Y.S.; Chung L.P.; Suen W.S.; Wang E.; Wong M.C.M.; Ho K.K.; Lam W.K.; Chiu S.W.; Girard L.; Minna J.D.; Gazdar A.F.; Wong M.P.;
Clin. Cancer Res. 12:1647-1653(2006)
Cited for: VARIANTS ALA-709; LYS-709; ALA-719; ASP-719; CYS-719; SER-719; SER-724; LYS-734; GLU-746 DEL; PHE-747; 747-LEU--GLU-749 DEL; PRO-748; 752-SER--ILE-759 DEL; ARG-787; MET-790; VAL-833; LEU-834; MET-858; ARG-858; GLN-861 AND GLU-873; POSSIBLE INVOLVEMENT IN LUNG CANCER;
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Chen Y.R.; Fu Y.N.; Lin C.H.; Yang S.T.; Hu S.F.; Chen Y.T.; Tsai S.F.; Huang S.F.;
Cited for: CHARACTERIZATION OF VARIANTS ALA-709; GLY-709; SER-719; ILE-768; VAL-833; LEU-835; VAL-838; ARG-858 AND GLN-861;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.